DexCom (DXCM) Stock Forecast & Price Target

$67.29

-0.24 (-0.36%)

(As of 09/27/2024 ET)

DexCom - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 18 Analyst Ratings

Sell
0

Hold
6

Buy
12

Based on 18 Wall Street analysts who have issued ratings for DexCom in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 6 have given a hold rating, 11 have given a buy rating, and 1 has given a strong buy rating for DXCM.

Consensus Price Target

$112.25
66.82% Upside

According to the 18 analysts' twelve-month price targets for DexCom, the average price target is $112.25. The highest price target for DXCM is $161.00, while the lowest price target for DXCM is $75.00. The average price target represents a forecasted upside of 66.82% from the current price of $67.29.

Get the Latest News and Ratings for DXCM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for DexCom and its competitors.

DXCM Analyst Ratings Over Time

Type	Current Forecast 9/29/23 to 9/28/24	1 Month Ago 8/30/23 to 8/29/24	3 Months Ago 7/1/23 to 6/30/24	1 Year Ago 9/29/22 to 9/29/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	11 Buy rating(s)	11 Buy rating(s)	11 Buy rating(s)	11 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$112.25	$112.25	$140.33	$134.25
Forecasted Upside	66.82% Upside	61.23% Upside	23.77% Upside	43.89% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Jovine Was Right in 2008—Will You Listen This Time? (Ad)

The stock market collapsed and didn't recover for an entire decade. And what we're facing today could be even worse. That's why the actions you take in the next 90 days could be crucial for your financial future.

Take these 4 steps today to protect your retirement NOW

DXCM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DXCM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

DexCom Stock vs. The Competition

Type	DexCom	Medical Companies	S&P 500
Consensus Rating Score	2.72	2.78	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	66.82% Upside	818.46% Upside	6.13% Upside
News Sentiment Rating	Neutral News See Recent DXCM News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/26/2024	Piper Sandler 2 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$90.00 ➝ $90.00	+20.74%
8/23/2024	Stifel Nicolaus 4 of 5 stars		Boost Target	Buy ➝ Buy	$90.00 ➝ $100.00	+38.35%
8/5/2024	Robert W. Baird 2 of 5 stars		Boost Target	Neutral ➝ Neutral	$80.00 ➝ $82.00	+13.42%
7/29/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$138.00 ➝ $113.00	+67.33%
7/26/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Johnson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/26/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$156.00 ➝ $120.00	+88.62%
Get the Latest News and Ratings for DXCM and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.
7/26/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$120.00 ➝ $75.00	+19.73%
7/26/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$163.00 ➝ $95.00	+49.42%
7/26/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$150.00 ➝ $115.00	+80.87%
7/26/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$165.00 ➝ $145.00	+125.82%
7/26/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$145.00 ➝ $80.00	-25.82%
7/26/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral	$145.00 ➝ $75.00	-30.46%
7/23/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$145.00 ➝ $145.00	+29.87%
5/30/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$130.00	+1.85%
4/26/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Strong-Buy ➝ Strong-Buy	$151.00 ➝ $160.00	+25.38%
4/3/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$148.00 ➝ $161.00	+15.86%
10/16/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kratky Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
10/16/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$110.00	+37.81%
2/10/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$114.00 ➝ $125.00	+16.56%
1/26/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$121.00	+16.35%
10/28/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$85.00 ➝ $114.00	-0.81%
10/12/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$125.00	+25.40%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:38 AM ET.

Should I Buy DexCom Stock? DXCM Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, September 21, 2024. Please send any questions or comments about these DexCom pros and cons to contact@marketbeat.com.

DexCom
Bull Case

Here are some ways that investors could benefit from investing in DexCom, Inc.:

DexCom's stock is currently trading at a lower price, potentially presenting a buying opportunity for investors looking to enter at a more favorable valuation.
The company has shown consistent revenue growth, with a 15.3% increase in revenue compared to the same quarter last year, indicating a positive trend in its financial performance.
DexCom's focus on continuous glucose monitoring (CGM) systems for diabetes management positions it well in a growing market segment with increasing demand for innovative healthcare solutions.
Despite recent fluctuations, DexCom has a strong market capitalization of $28.78 billion, reflecting investor confidence in the company's long-term prospects.
The company's earnings per share (EPS) performance has been solid, with DexCom surpassing analyst estimates in the latest quarterly report, showcasing its ability to deliver value to shareholders.

DexCom
Bear Case

Investors should be bearish about investing in DexCom, Inc. for these reasons:

Several brokerage firms have lowered their price targets on DexCom, indicating potential concerns about the company's future growth prospects or market conditions affecting its stock performance.
Analysts have adjusted ratings on DexCom, with some downgrading the stock from "buy" to "hold" or "neutral," suggesting a shift in sentiment towards the company's outlook.
The company's stock has experienced volatility, with fluctuations in trading volume and price movements, which may introduce uncertainty for investors seeking stability in their investments.
DexCom's debt-to-equity ratio of 1.00 may raise concerns about its financial leverage and ability to manage debt obligations, impacting its overall financial health and risk profile.
While DexCom has a strong product offering in CGM systems, competition in the healthcare technology sector is intense, potentially leading to challenges in maintaining market share and pricing power.

DXCM Forecast - Frequently Asked Questions

: According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for DexCom is $112.25, with a high forecast of $161.00 and a low forecast of $75.00.
: 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There are currently 6 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DXCM shares.
: According to analysts, DexCom's stock has a predicted upside of 66.82% based on their 12-month stock forecasts.
: Over the previous 90 days, DexCom's stock had 3 downgrades by analysts.
: DexCom has been rated by research analysts at Baird R W, Barclays, BTIG Research, Canaccord Genuity Group, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like DexCom less than other "medical" companies. The consensus rating score for DexCom is 2.72 while the average consensus rating score for "medical" companies is 2.78. Learn more on how DXCM compares to other companies.